Researchers at the University of California, San Francisco (UCSF), National Jewish Health and Pediatric Pneumology Center in Puerto Rico have been awarded nearly $ 10 million as part of a 5-year grant from the US National Heart Lung and Blood Institute, where asthma prevalence and deaths are among the highest in the world. The team plans to follow the children from birth through early childhood to study how genes and viral infections affect respiratory disease.
The new study, named the Puerto Rican Infant Metagenomic and Epidemiologic study of Respiratory Outcomes (FIRST), will be one of the largest US birth cohort studies ever conducted in a minority population.
A birth cohort is a special type of study in which newborn infants are enrolled and followed through childhood and potentially beyond to monitor exposures in early life and the onset of illnesses. Because the rate of asthma is so high in Puerto Rico, it is expected that many children will develop asthma, providing useful information to researchers to understand the causes.
"Creating a birth cohort is an extremely rare opportunity and uniquely positions us to answer fundamental questions about the early-life origins of asthma," said co-principal investigator Esteban G. Burchard, MD, MPH, of UCSF. "As a clinician, predicting development of asthma has been a challenge," said Jose Rodriguez-Santana.
"FIRST will help us discover why one baby can get very sick with a viral infection and develop asthma while another baby with the same viral infection has minimal symptoms and does not develop asthma."
Burchard and Rodriguez-Santana have collaborated for 20 years studying the genetics of asthma in Latin Americans. The new grant brings in researcher Max Seibold, PhD, of National Jewish Health, who has developed novel genetic techniques and strategies to easily obtain and analyze genetic samples from children's airways.
"Our prospective design and the genetic techniques we have pioneered will allow us to identify biological drivers of disease and biomarkers that may predict outcomes well before they are traditionally diagnosed," said Seibold.
Development of therapeutics
"These discoveries can inform development of therapeutics for early intervention and prevention of disease." The current grant provides funds to recruit 4,000 pregnant Puerto Rican women and 4,000 of their newborn infants over the next two years and track these infants' respiratory health for five years.
"This will make FIRST the first study to investigate how the airway develops in healthy and diseased states, from birth to childhood," said Sam Oh, PhD, MPH, director of epidemiology at the UCSF Asthma Collaborator, who is leading oversight of the FIRST study design and logistics.
"We hope that will lead to new insights about how to reduce asthma endemic to Puerto Rico." "With these children, we hope to extend this study to follow these children for chronicling their exposures and health outcomes in real time," Oh added. "Of course, that would depend on continued funding through the NIH or other sources such as philanthropy."
The team also hopes that additional funding will enable them to go beyond collecting airway cells from FIRST infants to also collect multiple tissue samples, including stem cells, urine, stool, and placenta tissue, and to cure these samples in a large biobank as a unique resource to study the factors affecting the health of PRIMERO participants throughout their lives.